ABBV · Earnings call · 2026Q3T · Full report

Product Launch and Transition

AbbVie Inc. · 2026-10-30 · Importance 40 · Surprise 42

AbbVie launched Skyrizi subcutaneous induction dosing for Crohn's disease, using the same on-body injector as its IBD maintenance dose; gastroenterologists and patients gave favorable feedback on ease of use, speed and comfort. Management expects the new option to strengthen Skyrizi's competitive position and accelerate new-patient share in Crohn's, although broad access typically takes around 60 days or somewhat longer to establish. The company said the AFFIRM results, including strong endoscopic outcomes, have resonated with gastroenterologists and expects rapid share acceleration into the first half of the following year.

Key facts

• AbbVie started a large Phase IIb program in Crohn's disease and ulcerative colitis evaluating Skyrizi plus ABBV-382 and Skyrizi plus ABBV-701.
• AbbVie recently began a Phase II study of Botox combined with Boey for glabellar lines.
• AbbVie received U.S. approval for Skyrizi subcutaneous induction in Crohn's disease.
• AbbVie began the commercial rollout of Boey in Europe and Canada.
• AbbVie expects rapid adoption of Epkinly in frontline DLBCL as it moves toward approvals, citing a simple addition to R-CHOP and payer receptivity.
• The selected 150-milligram emraclidine dose is five times the highest dose evaluated in the previous two pivotal trials.
• AbbVie reported that Epkinly plus R-CHOP reduced the risk of disease progression or death by 51% in frontline DLBCL patients with International Prognostic Index scores of 2 to 5.